Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Specific Glioma Prognostic Subtype Distinctions Based on DNA Methylation Patterns.

Chen X, Zhao C, Zhao Z, Wang H, Fang Z.

Front Genet. 2019 Sep 12;10:786. doi: 10.3389/fgene.2019.00786. eCollection 2019.

2.

Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.

Ma H, Zhao C, Zhao Z, Hu L, Ye F, Wang H, Fang Z, Wu Y, Chen X.

Cancer Gene Ther. 2019 Oct 16. doi: 10.1038/s41417-019-0142-6. [Epub ahead of print]

PMID:
31619751
3.

Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.

Zhang S, Wang Y, Gu Y, Zhu J, Ci C, Guo Z, Chen C, Wei Y, Lv W, Liu H, Zhang D, Zhang Y.

Mol Oncol. 2018 Jun;12(7):1047-1060. doi: 10.1002/1878-0261.12309. Epub 2018 May 21.

4.

Molecular subtypes of glioma identified by genome-wide methylation profiling.

Kloosterhof NK, de Rooi JJ, Kros M, Eilers PH, Sillevis Smitt PA, van den Bent MJ, French PJ.

Genes Chromosomes Cancer. 2013 Jul;52(7):665-74. doi: 10.1002/gcc.22062. Epub 2013 Apr 30.

PMID:
23629961
5.

DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups.

Chen W, Zhuang J, Wang PP, Jiang J, Lin C, Zeng P, Liang Y, Zhang X, Dai Y, Diao H.

Cancer Cell Int. 2019 Jul 16;19:185. doi: 10.1186/s12935-019-0900-4. eCollection 2019.

6.

Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.

Netanely D, Avraham A, Ben-Baruch A, Evron E, Shamir R.

Breast Cancer Res. 2016 Jul 7;18(1):74. doi: 10.1186/s13058-016-0724-2. Erratum in: Breast Cancer Res. 2016 Nov 28;18(1):117.

7.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

8.

DNA methylation data-based molecular subtype classification related to the prognosis of patients with cervical cancer.

Li C, Ke J, Liu J, Su J.

J Cell Biochem. 2019 Nov 3. doi: 10.1002/jcb.29491. [Epub ahead of print]

PMID:
31680300
9.

DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.

Zhang M, Zhang S, Wen Y, Wang Y, Wei Y, Liu H, Zhang D, Su J, Wang F, Zhang Y.

PLoS One. 2015 Nov 9;10(11):e0142279. doi: 10.1371/journal.pone.0142279. eCollection 2015.

10.

Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma.

Shen S, Wang G, Shi Q, Zhang R, Zhao Y, Wei Y, Chen F, Christiani DC.

Clin Epigenetics. 2017 Aug 24;9:88. doi: 10.1186/s13148-017-0392-9. eCollection 2017.

11.

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.

Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.

12.

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K, Wu A.

J Neurosurg. 2016 Jul;125(1):7-16. doi: 10.3171/2015.5.JNS142437. Epub 2015 Nov 6.

PMID:
26544773
13.

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.

EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.

14.

Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.

Pangeni RP, Zhang Z, Alvarez AA, Wan X, Sastry N, Lu S, Shi T, Huang T, Lei CX, James CD, Kessler JA, Brennan CW, Nakano I, Lu X, Hu B, Zhang W, Cheng SY.

Epigenetics. 2018;13(4):432-448. doi: 10.1080/15592294.2018.1469892. Epub 2018 Aug 6.

15.

Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.

Mishra NK, Guda C.

Oncotarget. 2017 Apr 25;8(17):28990-29012. doi: 10.18632/oncotarget.15993.

16.

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.

Tumour Biol. 2016 Oct;37(10):13571-13579. Epub 2016 Jul 28.

PMID:
27468718
17.

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.

Mur P, Rodríguez de Lope Á, Díaz-Crespo FJ, Hernández-Iglesias T, Ribalta T, Fiaño C, García JF, Rey JA, Mollejo M, Meléndez B.

J Neurooncol. 2015 May;122(3):441-50. doi: 10.1007/s11060-015-1738-9. Epub 2015 Feb 15.

PMID:
25682093
18.

Characterization of a prognostic four‑gene methylation signature associated with radiotherapy for head and neck squamous cell carcinoma.

Ma J, Li R, Wang J.

Mol Med Rep. 2019 Jul;20(1):622-632. doi: 10.3892/mmr.2019.10294. Epub 2019 May 24.

19.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

20.

Relation between Established Glioma Risk Variants and DNA Methylation in the Tumor.

Dahlin AM, Wibom C, Ghasimi S, Brännström T, Andersson U, Melin B.

PLoS One. 2016 Oct 25;11(10):e0163067. doi: 10.1371/journal.pone.0163067. eCollection 2016.

Supplemental Content

Support Center